- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.03. | Vigil Neuroscience GAAP EPS of -$0.57 in-line | 1 | Seeking Alpha | ||
| 26.03. | Vigil Neuroscience: Q4 Earnings Insights | 1 | Benzinga.com | ||
| 26.03. | Vigil Neuroscience, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 26.03. | Vigil Neuroscience, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 26.03. | Vigil Neuroscience, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.03. | Vigil Neuroscience, Inc.: Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | 168 | GlobeNewswire (Europe) | - Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP - - Enrollment for IGNITE trial completed with 20 patients... ► Artikel lesen | |
| 20.03. | Vigil Neuroscience appoints Kaufmann as Chief Medical Officer | 1 | Seeking Alpha | ||
| 20.03. | Vigil Neuroscience names new Chief Medical Officer | 1 | Investing.com | ||
| 20.03. | Vigil Neuroscience, Inc.: Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer | 102 | GlobeNewswire (Europe) | WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment... ► Artikel lesen | |
| 13.03. | Vigil Neuroscience, Inc.: Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 12.03. | Vigil Neuroscience, Inc.: Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days | 1 | GlobeNewswire (USA) | ||
| 06.03. | Vigil Neuroscience, Inc.: Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024 | 1 | GlobeNewswire (USA) | ||
| 11.01. | Vigil Neuroscience, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.01. | Vigil Neuroscience remains on track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 | 1 | Seeking Alpha | ||
| 03.01. | Vigil Neuroscience, Inc.: Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones | 255 | GlobeNewswire (Europe) | - On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 2024 - - Extends projected... ► Artikel lesen | |
| 22.11.23 | Vigil Neuroscience, Inc.: Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference | 1 | GlobeNewswire (USA) | ||
| 17.11.23 | Why Is Rare Neurological Disease Focused Vigil Neuroscience Stock Trading Lower Today? | 1 | Benzinga.com | ||
| 16.11.23 | Vigil Neuroscience reports interim Phase 2 data for ALSP drug candidate | 4 | Seeking Alpha | ||
| 16.11.23 | Vigil Neuroscience, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.11.23 | Vigil Neuroscience, Inc.: Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE | 181 | GlobeNewswire (Europe) | - Iluzanebart demonstrated favorable safety and tolerability, including no hematologic adverse events - - Clear CNS target engagement and downstream pharmacological activity at 20 mg/kg consistent... ► Artikel lesen |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 82,40 | +2,11 % | BioNTech SE: BioNTech veröffentlicht am 6. Mai 2024 Ergebnisse für das erste Quartal 2024 und informiert über operativen Fortschritt | MAINZ, Deutschland, 22. April 2024(Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Montag, den 6. Mai 2024, die Ergebnisse für das erste Quartal 2024 veröffentlichen. Darüber hinaus wird das... ► Artikel lesen | |
| VALNEVA | 3,526 | +0,51 % | Valneva Aktie: Trotz Rückschlag Analystenoptimismus | In der letzten Woche erlebte die Valneva Aktie eine Veränderung von 2,0 Prozent und steht aktuell bei 3,69 Euro. Der Kursrückgang am vergangenen Freitag um 2,6 Prozent sowie der beinahe 10-prozentige... ► Artikel lesen | |
| EPIGENOMICS | 1,545 | -5,21 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| NOVAVAX | 3,818 | +0,25 % | Novavax mit SCHOCK-MELDUNG: Könnte die Aktie am Montag komplett einbrechen - Das müssen Sie JETZT beachten!!! | ||
| DEFENCE THERAPEUTICS | 0,860 | +1,18 % | Kaufen nach Abverkauf? Defence Therapeutics, Infineon Technologies, Super Micro Computer, TSMC Aktie | Die Marktteilnehmer waren nach den starken Kursrückgängen von Dow Jones und DAX sehr nervös. Schon panikartig wurden in der Nacht zu Freitag viele Aktien und damit auch Indizes abverkauft. Erst in den... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,860 | +10,30 % | Looking Into Ginkgo Bioworks Holdings' Recent Short Interest | ||
| BEAM THERAPEUTICS | 21,360 | -1,11 % | Expert Ratings For Beam Therapeutics | ||
| ONCOLYTICS BIOTECH | 1,010 | -1,94 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,120 | +3,57 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
| ARCTURUS THERAPEUTICS | 26,550 | +1,45 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,828 | +5,49 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 8,790 | +1,74 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,730 | 0,00 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,230 | +7,86 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,140 | -1,29 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen |
Das Unternehmen VIGIL NEUROSCIENCE INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +5,04 % bei einem Aktienkurs von 2,710 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
